ESC-HFA 2024: Late-Breaking Science Video Collection

Published: 14 May 2024

  • Views:

    Views Icon 1067

  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Discover the latest heart failure data from impactful trials and studies presented at the Heart Failure Association’s annual congress, Heart Failure 2024. 

Dive deep into novel data with in-depth and critical discussions led by Late-breaker host Dr Harriette Van Spall and her expert guests. 

For quick and practical summaries of the late-breaking trials, watch our 5-minute Expert Interviews conducted with the investigators.

More from this programme

Part 1

Late-breaker Discussions with Dr Van Spall

Thought-provoking discussions with the investigators.
4 sessions
HFA 24 Late-Breaker Wrap Up with Dr Van Spall & Dr Petrie Watch now
Late-Breaker Discussion: The TITRATE-HF Study Watch now
Late-Breaker Discussion: Insights from the STEP-HFpEF Watch now
Late-Breaker Discussion: Findings from PACT-HF Watch now

Part 2

Expert Interviews

Short, practical interviews with the investigators.
8 sessions
Remote Patient Monitoring for Patients With Heart Failure: TELESAT Watch now
Cordella PA Sensor System in NYHA Class III HF Patients: PROACTIVE-HF Watch now
Aspirin Avoidance after Implantation of a Fully Magnetically Levitated LVAD: ARIES HM3 Watch now
Timing of Cardio-Kidney Protection with SGLT2i Watch now
Treatment Benefit Consistency of Remote Hemodynamic Monitoring in CHF: MONITOR-HF Subgroup Analysis Watch now
Inter-Atrial Shunt Treatment to Reduce Lung Congestion in Patients with Advanced Heart Failure: RELIEVE-HF Watch now
FINE-HEART: Design & Baseline Characteristics Watch now
HFA 24: The RELIEVE-HF Trial: Differential Effects of V-Wave Device Watch now

About the episode

HFA 24 - Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) joined onsite by Dr Jasper Brugts (Erasmus University Medical Centre, NL) to discuss the first results from the TITRATE-HF study.

TITRATE-HF is a real-world multicenter longitudinal study which aims to assess drug sequencing strategies for guideline-directed medical therapy (GDMT) initiation in patients with de novo, worsening and chronic heart failure, including dose titration patterns, intolerance for GDMT and the barriers for implementation. 4000 patients with heart failure with reduced ejection fraction (HFrEF) and heart failure with improved ejection fraction (HFimpEF) were enrolled across Dutch centers with a follow-up period of three years.

Findings showed that 44% of patients had received quadruple therapy and 1% received their target dose. The results suggested that it took some time for new drug classes to be implemented well, however, the uptake of SGLT2i seems to be faster than previous drug classes, such as ARNI. In terms of barriers for implementation, the results showed that side effects and intolerances of drugs were relevant as a reason for avoiding guideline directed medical therapies in HFrEF patients.

Recorded onsite at HFA 24, Lisbon.

Support: This is an independent discussion produced by Radcliffe Cardiology.

Editor: Mirjam Boros, Jordan Rance
Video Specialist: Tom Green, Oliver Miles
Interviewer: Jonathan McKenna

Faculty Biographies

Harriette Van Spall

Harriette Van Spall

Associate Professor of Medicine, Director of E-Health and Virtual Care

Dr Harriette Van Spall is an Associate Professor of Medicine and cardiologist and serves as Director of E-Health at McMaster University, Canada. She completed her medical and postgraduate clinical training at the University of Toronto and earned a Master of Public Health degree at Harvard University, US. Dr Van Spall is a Canadian Institutes of Health Research-funded clinical trialist and researcher with a focus on heart failure, health services, and health disparities.

She has garnered more than $4 million in research funding, has won several research awards, and has published her work in high-impact medical journals. She is an invited speaker, media correspondent, and editorial board member active in peer review at several high-impact medications journals and grant funding agencies, including Canadian Institutes of Health Research and Heart and Stroke Foundation of Canada.

Dr Van Spall is an Editorial Board…

View full profile
Jasper J Brugts

Jasper J Brugts

Heart Failure Cardiologist

Dr Jasper J Brugts is a Heart Failure Cardiologist at Erasmus University Medical Centre, Rotterdam, NL.

He is also a clinical epidemiologist and clinical trialist.

View full profile

Comments

You must be to comment. If you are not registered, you can register here.